BioMarin Pharmaceutical (BMRM) has gone up in 3 waves since the March crash and has been bouncing off the current support level for the past week. This support line is 100% from 1st wave and 61% from wave two. They have their trial drug BMN 270 for rare genetic disease Hemophilia A under priority review with FDA and expected action date of 21st August. (refer...
Biomarin Pharmaceutical Inc (BMRN - NASDAQ) has two different count, where either it already ended impulse as shown by roman letter, or its within 3rd wave cycle as shown in green roman letter. It is in 3rd internal wave of 5th subwave of 3rd wave, so stay bullish above 124.65 for the new high around 136-140 level.
Bullish breakout out of a 51 month scoop pattern makes a return to old highs a done deal. 150 is exactly the target of the massive bullish scoop pattern (based on daily closes), whose breakout-and-backtest are in the books. Price is currently locked inside a very steep rising channel, which will yield 150 as soon as July 27 (earnings reporting day......
biotech bubble will pop, but even before that this rising wedge looks bearish, at least for a quick scalp to support
Hey people, BIOMARIN PHARMACEUTICAL is in a compression zone, great potential to break from above to breakout the stabilization zone. Please LIKE & FOLLOW, thank you!
It break out the pivot. Both the volume and RSI are weak. possible pull back to $92
BMRN is in a Wave 4 of 5 impulse move. Target is 98-100 by end of Feb early March.
Waiting for at least 3 closes above the 200sma to confirm new uptrend.
Looks like there's an inverse head and shoulders pattern forming whose price target would exactly hit the long term trend line. Waiting on formation and/or break confirmation to enter long.
BMRN - belongs to the medical industry. Biomarine is an American biotechnology company focused on enzyme replacement therapy. On August 1, it reported financial results for the second quarter of 2019. Revenue for the quarter was $ 387.8 million, up 4% from $ 372.8 million for the same period last year. The net loss was $ 37.4 million, compared to a net loss of $...
Morningstar weekly highlights set Biomarin Pharmaceuticals with an amazing $119 fair price value ( 50% above current price). Rating: 4 stars Uncertainty rating: Medium Moat: Narrow